CSF3R mutations co-occur with CEBPA mutations in pediatric AML. (A) Schematic showing the locations of CSF3R mutations found in pediatric AML. One patient had both the T618I and T615A mutations. (B) The percentage of cytogenetic abnormalities (obtained from clinical data) or gene mutations for patients with transforming CSF3R mutations (gray) or CSF3R non-mutated cases (red) are shown. (C) Transforming CSF3R mutation overlap with other gene mutations. The most frequent genomic alterations are shown by OncoPrint analysis. Each column represents a case with a transforming CSF3R mutation. Mutations are represented by a gray square. Some 74% of these cases have either a CBF rearrangement or CEBPA mutation, and there is very minimal overlap between CBF and CEBPA. Custom OncoPrints were generated using the OncoPrinter function of the cBioPortal website (www.cbioportal.org). FNIII, fibronectin type III; IDH2, isocitrate dehydrogenase 2; IgG, immunoglobulin G; KIT, KIT proto-oncogene receptor tyrosine kinase; WT, wild-type.